-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HPN-328 in Bladder Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HPN-328 in Bladder Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. HPN-328 in Bladder Cancer Drug Details: HPN-328 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HPN-328 in Thymic Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HPN-328 in Thymic Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. HPN-328 in Thymic Carcinoma Drug Details: HPN-328 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HPN-328 in Small-Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HPN-328 in Small-Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. HPN-328 in Small-Cell Lung Cancer Drug Details: HPN-328 is under development...
-
Product Insights
Thymic Carcinoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Thymic Carcinoma - Drugs In Development, 2023’, provides an overview of the Thymic Carcinoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Thymic Carcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Thymoma (Thymic Epithelial Tumor) – Drugs In Development, 2023
Global Markets Direct’s, ‘Thymoma (Thymic Epithelial Tumor) - Drugs In Development, 2023’, provides an overview of the Thymoma (Thymic Epithelial Tumor) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Thymoma (Thymic Epithelial Tumor), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Colorectal Tumor – Drugs In Development, 2023
Global Markets Direct’s, ‘Colorectal Tumor - Drugs In Development, 2023’, provides an overview of the Colorectal Tumor pipeline landscape. The report provides comprehensive information on the therapeutics under development for Colorectal Tumor, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ASP-3082 in Pancreatic Ductal Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ASP-3082 in Pancreatic Ductal Adenocarcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ASP-3082 in Pancreatic Ductal Adenocarcinoma Drug Details: ASP-3082 is under development...
-
Product Insights
NewNet Present Value Model: Harpoon Therapeutics Inc’s HPN-536
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GM-2505 in Depression
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. GM-2505 in Depression Drug Details: GM-2505 is under development for the treatment of depression and...
-
Product Insights
NewNet Present Value Model: TScan Therapeutics Inc’s TSC-100/TSC-101
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.